Blood Pressure Medications Explained: The Four Main Classes and What Makes Each One Different

If you’ve been prescribed a blood pressure medication, there’s a good chance you know its name but not much else about it. What class it belongs to. How it actually lowers blood pressure. Why your doctor chose it over alternatives. What side effects are real versus overstated. Whether it interacts with anything you’re already taking.

These are reasonable things to want to know about a medication you’ll likely be taking indefinitely. This article covers the four main classes of blood pressure medications – ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics – plus beta-blockers, which remain important in specific situations.

Why There Are Multiple Drug Classes

Hypertension can be driven by different physiological mechanisms: excess fluid volume, excessive vasoconstriction, overactivation of the renin-angiotensin-aldosterone system (RAAS), elevated cardiac output, increased arterial stiffness. Different drug classes target different mechanisms – which is why blood pressure that doesn’t respond adequately to one class often responds to another or to combination therapy.

It’s also why choosing the right medication isn’t always straightforward. Age, ethnicity, comorbid conditions, and individual response all influence which drug or combination works best.

Class 1: ACE Inhibitors

How they work: ACE inhibitors (angiotensin-converting enzyme inhibitors) block the enzyme that converts angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor and also stimulates aldosterone release (which causes sodium and water retention). Blocking its production dilates blood vessels and reduces fluid volume – lowering blood pressure through both mechanisms.

Common ACE inhibitors:

• Lisinopril (Zestril, Prinivil) – most commonly prescribed
• Enalapril (Vasotec)
• Ramipril (Altace)
• Benazepril (Lotensin)
• Captopril (Capoten) – shorter-acting, less commonly used now

When ACE inhibitors are particularly preferred:

• Diabetes with hypertension: ACE inhibitors have additional kidney-protective effects (nephroprotective) beyond blood pressure lowering – they reduce intraglomerular pressure and slow progression of diabetic nephropathy. The ADA recommends ACE inhibitors (or ARBs) as first-line antihypertensives for diabetics with any degree of proteinuria.
• Chronic kidney disease with proteinuria: Same nephroprotective mechanism applies
• Heart failure with reduced ejection fraction: ACE inhibitors reduce mortality in heart failure; one of the most evidence-backed indications in cardiology
• Post-myocardial infarction: ACE inhibitors started early after MI reduce mortality and left ventricular remodeling

The ACE inhibitor cough: ACE inhibitors cause a persistent dry cough in approximately 10-15% of users (higher in Asian populations – up to 30-40%). The mechanism: ACE is also responsible for breaking down bradykinin; when ACE is inhibited, bradykinin accumulates and causes airway irritation. The cough is not dangerous but is often intolerable. This is the primary reason to switch to an ARB.

Contraindications:

• Pregnancy (category D/X – can cause severe fetal renal damage and death; must be stopped immediately if pregnancy occurs)
• History of angioedema (life-threatening facial/airway swelling) from any ACE inhibitor
• Bilateral renal artery stenosis
• Hyperkalemia

Potassium elevation: ACE inhibitors reduce aldosterone, which normally promotes potassium excretion. This can cause hyperkalemia – particularly in patients with CKD, those taking potassium supplements, or those on potassium-sparing diuretics. Monitor potassium after starting.

Class 2: ARBs (Angiotensin Receptor Blockers)

How they work: ARBs block the angiotensin II receptor (AT1 receptor) directly, rather than preventing angiotensin II formation. The blood pressure lowering effect is similar to ACE inhibitors – vasodilation and reduced aldosterone – but the mechanism is downstream.

Common ARBs:

• Losartan (Cozaar) – also has mild uricosuric effect (lowers uric acid – relevant in gout)
• Valsartan (Diovan)
• Olmesartan (Benicar)
• Irbesartan (Avapro)
• Telmisartan (Micardis)
• Candesartan (Atacand)

ACE inhibitors vs ARBs: The indications and contraindications are nearly identical. The primary practical difference is that ARBs essentially never cause the dry cough that ACE inhibitors do (because bradykinin is still broken down when the receptor is blocked rather than the enzyme inhibited). ARBs are often used as the default switch when an ACE inhibitor cough is intolerable.

The evidence for cardiovascular and renal outcomes between the two classes is broadly similar. There was historical debate about whether ACE inhibitors were superior for certain outcomes – the current consensus is they’re largely interchangeable for most indications.

Angioedema: ARBs can also cause angioedema, but at a significantly lower rate than ACE inhibitors. People who develop angioedema on an ACE inhibitor may (cautiously, with monitoring) be switched to an ARB, though some cross-reactivity exists.

Pregnancy: Same contraindication as ACE inhibitors – must not be used in pregnancy.

Combination of ACE inhibitor + ARB: This combination was studied in the ONTARGET trial and found to increase adverse events (hypotension, hyperkalemia, kidney injury) without additional cardiovascular benefit. The combination is not recommended.

Class 3: Calcium Channel Blockers (CCBs)

How they work: Calcium channel blockers prevent calcium ions from entering vascular smooth muscle cells and (for certain types) cardiac muscle cells. Calcium is required for muscle contraction – blocking its entry causes vasodilation (blood vessels relax and dilate), lowering peripheral vascular resistance and therefore blood pressure.

Two main types:

Dihydropyridines (DHP-CCBs) – act primarily on vascular smooth muscle; minimal cardiac effects at standard doses:

• Amlodipine (Norvasc) – most prescribed CCB; long half-life (once daily, stable blood levels)
• Nifedipine (Adalat, Procardia) – short-acting forms are now rarely used for hypertension
• Felodipine, nisoldipine, nicardipine

Non-dihydropyridines – act on both vascular and cardiac muscle; slow heart rate and reduce contractility:

• Diltiazem (Cardizem, Tiazac)
• Verapamil (Calan, Isoptin)

When CCBs are particularly preferred:

• Older adults: CCBs and thiazide diuretics are particularly effective and well-tolerated in older patients, who often have higher systolic hypertension driven by arterial stiffness
• Black American patients: CCBs and thiazides are generally more effective than ACE inhibitors or ARBs as monotherapy in Black patients (who tend to have lower renin hypertension, where RAAS inhibition is less effective alone). The ALLHAT trial specifically demonstrated this – chlorthalidone and amlodipine performed at least as well as lisinopril in Black patients
• Angina: DHP-CCBs reduce cardiac oxygen demand (vasodilation reduces afterload); non-DHP CCBs reduce heart rate
• Raynaud’s phenomenon: CCBs reduce vasospasm
• Atrial fibrillation rate control: Non-DHP CCBs (diltiazem, verapamil) slow AV conduction

Common side effects of DHP-CCBs:

• Peripheral edema (ankle swelling): The most common reason for discontinuation – affects approximately 5-15% of users. This is not cardiac edema (not a sign of heart failure) – it’s caused by local capillary leakage from vasodilation. It responds to dose reduction, adding an ACE inhibitor/ARB (which counter the local capillary effect), or switching medications. It does not respond to diuretics in the same way as cardiac edema.
• Flushing and headache (more common with short-acting formulations)
• Reflex tachycardia (more common with short-acting nifedipine – this is why short-acting nifedipine is no longer used for chronic hypertension)

Non-DHP CCB concerns:

• Both diltiazem and verapamil slow the heart and can cause bradycardia and AV block
• Verapamil causes significant constipation
• Important drug interaction: Both diltiazem and verapamil inhibit CYP3A4, dramatically increasing levels of drugs metabolized by this enzyme – including statins (simvastatin, lovastatin), increasing myopathy risk. Always check interactions when these are prescribed.
• Non-DHP CCBs are contraindicated in heart failure with reduced ejection fraction (they reduce cardiac contractility)

Class 4: Thiazide Diuretics

How they work: Thiazide diuretics (and the thiazide-like diuretics chlorthalidone and indapamide) block sodium-chloride cotransporters in the distal convoluted tubule of the kidney, reducing sodium and water reabsorption. The initial blood pressure effect is from volume reduction; with continued use, vasodilatory effects become more prominent.

Common thiazide diuretics:

• Hydrochlorothiazide (HCTZ) – most commonly prescribed thiazide in the US
• Chlorthalidone (Thalitone) – stronger and longer-acting than HCTZ; preferred by many guidelines based on outcomes data
• Indapamide – has additional vasodilatory properties; less metabolic side effects

HCTZ vs chlorthalidone: Multiple hypertension experts and guidelines have noted that chlorthalidone has better evidence for cardiovascular outcome reduction than HCTZ, despite HCTZ being prescribed far more frequently. The ALLHAT trial used chlorthalidone; the outcomes evidence for HCTZ is less robust. Many cardiologists prefer chlorthalidone when a thiazide is indicated.

When thiazides are particularly preferred:

• Older adults with isolated systolic hypertension: Very effective in this common pattern
• Black American patients: One of the most effective classes as monotherapy (along with CCBs)
• Osteoporosis: Thiazides reduce urinary calcium excretion and have a mild bone-protective effect – a secondary benefit in patients with osteoporosis risk
• Combination therapy: Thiazides work well in combination with most other antihypertensives and are frequently used as the second or third agent in combination regimens

Common side effects and monitoring:

• Hypokalemia (low potassium): Thiazides increase potassium excretion. Monitor potassium after starting; supplement if needed; avoid other potassium-depleting drugs without monitoring
• Hyponatremia (low sodium): Particularly in older adults; monitor sodium
• Elevated uric acid: Thiazides reduce uric acid excretion, raising serum uric acid – may precipitate gout in susceptible individuals
• Elevated blood glucose: Thiazides modestly impair insulin secretion; may worsen glucose control in diabetics or increase risk in prediabetes
• Elevated triglycerides and cholesterol: Modest metabolic effect; less concern at low doses
• Erectile dysfunction: More common than with other classes; less likely with low doses

Hypokalemia and potassium monitoring: This is the most important safety monitoring point for thiazides. Low potassium causes muscle weakness, cramps, arrhythmias (particularly problematic in patients already on digoxin). Check potassium 1-4 weeks after starting or increasing dose.

Class 5: Beta-Blockers

Beta-blockers are not recommended as first-line therapy for uncomplicated hypertension in most current guidelines (they’ve been displaced by the four classes above), but remain important in specific situations.

How they work: Beta-blockers competitively block beta-adrenergic receptors. Beta-1 receptors in the heart: blocking reduces heart rate and contractility (reducing cardiac output). Beta-2 receptors in blood vessels and lungs: blocking causes vasoconstriction and bronchoconstriction (why beta-blockers are relatively contraindicated in asthma/COPD).

Common beta-blockers:

• Metoprolol succinate (Toprol-XL) – cardioselective (beta-1 predominant), once daily, most used
• Atenolol (Tenormin) – cardioselective; once daily
• Bisoprolol (Zebeta) – highly cardioselective
• Carvedilol (Coreg) – non-selective, also blocks alpha-1 receptors (additional vasodilation)
• Propranolol (Inderal) – non-selective; also used for migraine prevention, performance anxiety, thyrotoxicosis, tremor

When beta-blockers are specifically indicated:

• Heart failure with reduced ejection fraction (HFrEF): Three beta-blockers (carvedilol, metoprolol succinate, bisoprolol) have mortality benefit in heart failure – a guideline-directed indication
• Post-myocardial infarction: Reduce mortality and reinfarction risk
• Angina: Reduce cardiac oxygen demand by slowing heart rate
• Rate control in atrial fibrillation
• Migraine prevention
• Essential tremor
• Hyperthyroidism (thyrotoxicosis) – short-term symptom control

Side effects and concerns:

• Fatigue and exercise intolerance (reduced maximum heart rate)
• Cold hands and feet (peripheral vasoconstriction)
• Erectile dysfunction
• Masking hypoglycemia symptoms in diabetics on insulin (tachycardia from hypoglycemia is blunted)
• Relative contraindication in asthma/COPD – bronchoconstriction (less concern with highly cardioselective agents at low doses)
• Do not abruptly stop – can cause rebound hypertension, angina, or MI in susceptible patients; always taper

Combination Therapy: The Reality of Modern Hypertension Treatment

Most people with hypertension ultimately need more than one medication to reach target blood pressure. This is not a treatment failure – it’s the nature of a multifactorial condition.

Common effective combinations:

• ACE inhibitor (or ARB) + CCB: Complementary mechanisms; the RAAS inhibitor also reduces CCB-related ankle edema
• ACE inhibitor (or ARB) + thiazide diuretic: Very commonly used; complementary mechanisms, RAAS inhibitor reduces hypokalemia from thiazide
• ACE inhibitor (or ARB) + CCB + thiazide: A triple combination used when two drugs are insufficient
• Fixed-dose combination pills: Multiple combination pills exist (e.g., amlodipine/valsartan, amlodipine/benazepril) that simplify regimens and improve adherence

What doesn’t combine: ACE inhibitor + ARB (increases adverse events without additional benefit, per ONTARGET). Two drugs from the same class.

Frequently Asked Questions

Why does my doctor change my blood pressure medication sometimes even if my blood pressure is controlled? Several reasons: side effects that develop over time, changes in your other medical conditions (new diagnosis of diabetes, heart failure, or CKD may shift the preferred agent), new evidence updating guidelines, or pregnancy changing the safety profile of your current medication. Sometimes cost or insurance coverage changes also drive switches.

Why do I need medication when lifestyle changes could help? Lifestyle changes – dietary sodium reduction, weight loss, exercise, limiting alcohol, DASH diet – can lower blood pressure meaningfully (5-15 mmHg systolic in many patients). For mild hypertension, lifestyle alone may be sufficient initially. For moderate-to-severe hypertension, or when cardiovascular risk is elevated, medication provides faster and more reliable protection while lifestyle changes are implemented. Most people benefit from both, not one or the other.

My blood pressure is controlled on medication. Can I stop? For most people with established hypertension, stopping medication allows blood pressure to return to its elevated baseline – the medication is controlling it, not curing it. Some people who achieve significant weight loss and lifestyle modification can reduce or discontinue medication under medical supervision. This requires careful monitoring and a deliberate plan with your doctor – not unilateral discontinuation.

Is it dangerous to miss a dose of blood pressure medication? Missing an occasional dose is usually not dangerous – blood pressure rises somewhat but a single missed dose rarely causes acute crisis. However, regularly missing doses significantly reduces cardiovascular protection. Establishing a daily routine (taking medication at the same time, linked to another habit) is the practical solution. Never double up on missed doses.

Do I need to monitor my blood pressure at home? Yes – for most patients on blood pressure medication, home monitoring is recommended. Home blood pressure provides more representative readings than clinic measurements (which can be affected by “white coat hypertension”) and helps track whether medication is adequately controlling blood pressure across the day. A validated upper-arm cuff (not wrist monitors) used consistently at the same time of day provides the most useful information.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Blood pressure medication selection and dosing should be individualized by a qualified healthcare provider based on your complete medical history, comorbidities, other medications, and blood pressure pattern. Do not start, stop, or change blood pressure medications without medical guidance.

References

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA hypertension guideline. Journal of the American College of Cardiology. 2018;71(19):e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006
2. ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. https://doi.org/10.1001/jama.288.23.2981
3. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). New England Journal of Medicine. 2008;358(15):1547-1559. https://doi.org/10.1056/NEJMoa0801317
4. American Heart Association. Types of blood pressure medications. https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
5. National Heart, Lung, and Blood Institute (NHLBI). High blood pressure. https://www.nhlbi.nih.gov/health/high-blood-pressure
6. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
7. MedlinePlus. High blood pressure medicines. https://medlineplus.gov/highbloodpressuremedicines.html
8. Pimenta E, Oparil S. Management of hypertension in the elderly. Nature Reviews Cardiology. 2012;9(5):286-296. https://doi.org/10.1038/nrcardio.2012.27
9. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. Journal of Clinical Hypertension. 2011;13(9):639-643. https://doi.org/10.1111/j.1751-7176.2011.00519.x
10. Centers for Disease Control and Prevention (CDC). High blood pressure. https://www.cdc.gov/blood-pressure/index.html